Right Heart Involvement in Haematologic Disorders

  • Ana-Maria Vintilă
  • Mihaela Horumbă
  • Vlad Damian Vintilă


Haematologic patients are set apart by specific complications like immunosuppression, thrombocytopenia, sometimes associating coagulopathy and multiple points of entry for infection (central venous catheters and mucositis).

The right-sided heart is of particular importance in this type of patients as it is the preferred location of both primary and secondary cardiac tumours and is more frequently affected by radiation therapy due to its more anterior position in the thorax.

Chemotherapeutics may determine pulmonary hypertension and thus put a strain on the right ventricle.

Moreover, investigation of right-heart parameters like tricuspid annular plane systolic excursion and strain rate may reveal early cardiac dysfunction and establish prognosis in cardiac amyloidosis.


Primary cardiac lymphoma Cardiac metastases Cardiotoxicity Radiation therapy Anthracyclines Tricuspid endocarditis AL amyloidosis Right ventricle dysfunction Right heart failure Haematologic malignancies 


  1. 1.
    Nikdoust F, Sani ZA, Tabatabaei SA. Right ventricle tumoral mass in acute promyelocytic leukemia (AML M3): cardiac magnetic resonance findings. Iranian Heart J. 2016;17(3):46–50.Google Scholar
  2. 2.
    Young J, Goldman IR. Tumor metastasis to the heart. Circulation. 1954;9(2):220–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Amano J, Nakayama J, Yoshimura Y, Ikeda U. Clinical classification of cardiovascular tumors and tumor-like lesions, and its incidences. Gen Thorac Cardiovasc Surg. 2013;61(8):435–47.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Goudie RB. Secondary tumours of the heart and pericardium. Br Heart J. 1955;17(2):183.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Laws JW, Annes GP, Bogren HG. Primary malignant tumors of the heart. Calif Med. 1973;118(4):11.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Mukai K, Shinkai T, Tominaga K, Shimosato Y. The incidence of secondary tumors of the heart and pericardium: a 10-year study. Jpn J Clin Oncol. 1988;18(3):195–201.PubMedGoogle Scholar
  7. 7.
    Hanfling SM. Metastatic cancer to the heart. Circulation. 1960;22(3):474–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Voigt P, Wienbeck S, Weber M-A, Oyama-Manabe N, Beimler M, Schob S, et al. Cardiac hematological malignancies: typical growth patterns, imaging features, and clinical outcome. Angiology. 2017;69(2):170–6. Scholar
  9. 9.
    Barbaric D, Holley D, Lau K-C, McCowage G. It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis. Leuk Lymphoma. 2002;43(12):2417–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Skhvatsabaja L. Secondary malignant lesions of the heart and pericardium in neoplastic disease. Oncology. 1986;43(2):103–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Perry DJ, McCormick D, Veasey S, Cohen IS. Right heart obstruction due to intracavitary prolymphocytic leukemia. Am J Med. 1986;81(1):131–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Dingerkus H, Völler H, Albrecht A, Hennig L, Stein H, Schröder R. Mediastinal chloroma affecting the right heart with superior vena cava syndrome. Am Heart J. 1994;127(2):465–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Makaryus AN, Tung F, Liu W, Mangion J, Kort S. Extensive neoplastic cardiac infiltration in a patient with acute myelogenous leukemia: role of echocardiography. Echocardiography. 2003;20(6):539–44.CrossRefPubMedGoogle Scholar
  14. 14.
    Hunkeler N, Canter CE. Antemortem diagnosis of gross cardiac metastasis in childhood leukemia: echocardiographic demonstration. Pediatr Cardiol. 1990;11(4):225–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Foucar K, Foucar E, Willman C, Horvath A, Gerety RL. Nonleukemic granulocytic sarcoma of the heart: a report of a fatal case. Am J Hematol. 1987;25(3):325–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Marcos-Alberca P, Ibáñez B, Rey M, Román A, Rábago R, Orejas M, et al. Cardiac granulocytic sarcoma (chloroma): in vivo diagnosis with transesophageal echocardiography. J Am Soc Echocardiogr. 2004;17(9):1000–2.CrossRefPubMedGoogle Scholar
  17. 17.
    Mawad R, Wu D, Abkowitz JL, Walter RB. Myeloid sarcoma of the heart. Leuk Lymphoma. 2012;53(12):2511–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Attallah A, Cheong BY, Bernicker E, Wilson JM. Cardiac chloroma: novel presentation and subsequent diagnosis with cardiac magnetic resonance imaging. Tex Heart Inst J. 2010;37(2):242.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Mignano JE, Chan MD, Rosenwald IB, Kimmelstiel CD, Wolfe LC. Intracardiac chloroma. J Pediatr Hematol Oncol. 2009;31(12):977–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Fernandez L, Couban S, Sy R, Miller R. An unusual presentation of extramedullary plasmacytoma occurring sequentially in the testis, subcutaneous tissue, and heart. Am J Hematol. 2001;67(3):194–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Singh B, Lahiri A, Kakar P. Extramedullary plasmacytoma. J Laryngol Otol. 1979;93(12):1239–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1(4):255–62.CrossRefPubMedGoogle Scholar
  23. 23.
    Keung Y, Lau S, Gill P. Extramedullary plasmacytoma of the heart presenting as cardiac emergency: review of literature. Am J Clin Oncol. 1994;17(5):427–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Nanjappa MC, Shankarappa RK, Kalpana SR, Bhat P, Moorthy N. Intracardiac thrombi in acute myeloid leukemia: an echocardiographic and autopsy correlation. Echocardiography. 2010;27(1):E4–8.CrossRefPubMedGoogle Scholar
  25. 25.
    McAllister HA, Hall RJ, Cooley DA. Tumors of the heart and pericardium. Curr Probl Cardiol. 1999;24(2):59–116.CrossRefGoogle Scholar
  26. 26.
    Roberts WC, Glancy DL, Devita VT. Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides): a study of 196 autopsy cases. Am J Cardiol. 1968;22(1):85–107.CrossRefPubMedGoogle Scholar
  27. 27.
    Curtsinger CR, Wilson MJ, Yoneda K. Primary cardiac lymphoma. Cancer. 1989;64(2):521–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Chalabreysse L, Berger F, Loire R, Devouassoux G, Cordier J-F, Thivolet-Bejui F. Primary cardiac lymphoma in immunocompetent patients: a report of three cases and review of the literature. Virchows Arch. 2002;441(5):456–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Petrich A, Cho SI, Billett H. Primary cardiac lymphoma. Cancer. 2011;117(3):581–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Gowda RM, Khan IA. Clinical perspectives of primary cardiac lymphoma. Angiology. 2003;54(5):599–604.CrossRefPubMedGoogle Scholar
  31. 31.
    Nakayama Y, Uchimoto S, Tsumura K, Morii H. Primary cardiac lymphoma with infiltration of the atrioventricular node: remission with reversal of the atrioventricular block induced by chemotherapy. Cardiology. 1997;88(6):613–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Legault S, Couture C, Bourgault C, Bergeron S, Poirier P, Sénéchal M. Primary cardiac Burkitt-like lymphoma of the right atrium. Can J Cardiol. 2009;25(3):163–5.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Miguel CE, Bestetti RB. Primary cardiac lymphoma. Int J Cardiol. 2011;149(3):358–63.CrossRefPubMedGoogle Scholar
  34. 34.
    Chim C, Chan A, Kwong Y, Liang R. Primary cardiac lymphoma. Am J Hematol. 1997;54(1):79–83.CrossRefPubMedGoogle Scholar
  35. 35.
    Woods J, Monteiro P, Rhodes A. Right ventricular dysfunction. Curr Opin Crit Care. 2007;13(5):532–40.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Fortún J. Principales infecciones en el paciente oncológico: manejo práctico. An Sist Sanit Navar. 2004.Google Scholar
  37. 37.
    Chen K-W, Chang J-H, Yeh S-P, Lu C-R. Primary cardiac B-cell lymphoma with atrioventricular block and paroxysmal ventricular tachycardia. J Cardiothorac Surg. 2012;7(1):70.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Dorsay TA, Ho VB, Rovira MJ, Armstrong MA, Brissette MD. Primary cardiac lymphoma: CT and MR findings. J Comput Assist Tomogr. 1992;17(6):978–81.CrossRefGoogle Scholar
  39. 39.
    Mügge A, Daniel WG, Haverich A, Lichtlen PR. Diagnosis of noninfective cardiac mass lesions by two-dimensional echocardiography. Comparison of the transthoracic and transesophageal approaches. Circulation. 1991;83(1):70–8.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Moore JA, DeRan BP, Minor R, Julie A, Fraker TD. Transesophageal echocardiographic evaluation of intracardiac lymphoma. Am Heart J. 1992;124(2):514–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Cho SW, Kang YJ, Kim TH, Cho SK, Hwang MW, Chang W, et al. Primary cardiac lymphoma presenting with atrioventricular block. Korean Circ J. 2010;40(2):94–8.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Ceresoli GL, Ferreri AJ, Bucci E, Ripa C, Ponzoni M, Villa E. Primary cardiac lymphoma in immunocompetent patients. Cancer. 1997;80(8):1497–506.CrossRefPubMedGoogle Scholar
  43. 43.
    Nielsen KM, Offersen BV, Nielsen HM, Vaage-Nilsen M, Yusuf SW. Short and long term radiation induced cardiovascular disease in patients with cancer. Clin Cardiol. 2017;40(4):255–61.CrossRefPubMedGoogle Scholar
  44. 44.
    Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiol Res Pract. 2011;2011:317659.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Tadic M, Cuspidi C, Hering D, Venneri L, Grozdic-Milojevic I. Radiotherapy-induced right ventricular remodelling: the missing piece of the puzzle. Arch Cardiovasc Dis. 2017;110(2):116–23.CrossRefPubMedGoogle Scholar
  46. 46.
    Brosius FC, Waller BF, Roberts WC. Radiation heart disease: analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70(3):519–30.CrossRefPubMedGoogle Scholar
  47. 47.
    Burger A, Loffler H, Bamberg M, Rodemann HP. Molecular and cellular basis of radiation fibrosis. Int J Radiat Biol. 1998;73(4):401–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Khakoo AY, Yeh ET. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol. 2008;5(11):655–68.CrossRefPubMedGoogle Scholar
  50. 50.
    Torbey E, Yacoub H, McCord D, Lafferty J. Two cases and review of the literature: primary percutaneous angiography and antiplatelet management in patients with immune thrombocytopenic purpura. ISRN Hematol. 2013;2013:174659.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Slama MS, Guludec D, Sebag C, Leenhardt AR, Davy J, Pellerin DE, et al. Complete atrioventricular block following mediastinal irradiation: a report of six cases. Pacing Clin Electrophysiol. 1991;14(7):1112–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, et al. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014;9(10):1554–60.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Orzan F, Brusca A, Gaita F, Giustetto C, Figliomeni M, Libero L. Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol. 1993;39(2):151–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy. Circulation. 2004;109(25):3122–31.CrossRefPubMedGoogle Scholar
  55. 55.
    Tadic M, Cuspidi C, Hering D, Venneri L, Danylenko O. The influence of chemotherapy on the right ventricle: did we forget something? Clin Cardiol. 2017;40(7):437–43.CrossRefPubMedGoogle Scholar
  56. 56.
    Vejpongsa P, Yeh E. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95(1):45–52.CrossRefPubMedGoogle Scholar
  57. 57.
    Lemez P. Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia. J Clin Oncol. 1997;15(10):3293–5.CrossRefPubMedGoogle Scholar
  58. 58.
    Sabatino J, Yauda M, De Rosa S, Tamme L, Ianconetti C, Albanese M, Mignona C, Aquila I, Donato G, Indolfi C. Empagliflozin reduces the doxorubicine-induced myocardial dysfunction. Eur Heart J. 2017.
  59. 59.
    Kong JH, Jeon Y-W, Lee S-E, Choi SY, Kim S-H, Oh YJ, et al. Long-term assessment of Dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia. Blood. 2014;124:5535.Google Scholar
  60. 60.
    Yun S, Anwer F, Vincelette ND. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia. BMJ Case Rep. 2014;2014:bcr2014204477.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Lenčová-Popelová O, Jirkovský E, Mazurová Y, Lenčo J, Adamcová M, Šimůnek T, et al. Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PLoS One. 2014;9(5):e96055.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Murbraech K, Holte E, Broch K, Smeland KB, Holte H, Rösner A, et al. Impaired right ventricular function in long-term lymphoma survivors. J Am Soc Echocardiogr. 2016;29(6):528–36.CrossRefPubMedGoogle Scholar
  63. 63.
    Christiansen JR, Massey R, Dalen H, Kanellopoulos A, Hamre H, Ruud E, et al. Right ventricular function in long-term adult survivors of childhood lymphoma and acute lymphoblastic leukaemia. Eur Heart J Cardiovasc Imaging. 2016;17(7):735–41.CrossRefPubMedGoogle Scholar
  64. 64.
    Calleja A, Poulin F, Khorolsky C, Shariat M, Bedard PL, Amir E, et al. Right ventricular dysfunction in patients experiencing cardiotoxicity during breast cancer therapy. J Oncol. 2015;2015:609194.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Chan P, Ogilby JD, Segal B. Tricuspid valve endocarditis. Am Heart J. 1989;117(5):1140–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Chaudhary N, Vishwanath M, Pahuja M, Borker A. Candida albicans endocarditis in a child with acute lymphoblastic leukemia: a dreaded complication of intensive chemotherapy. Indian J Med Paediatr Oncol. 2013;34(1):28.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Nandakumar R, Raju G. Isolated tricuspid valve endocarditis in nonaddicted patients: a diagnostic challenge. Am J Med Sci. 1997;314(3):207–12.PubMedGoogle Scholar
  68. 68.
    Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435–86.CrossRefPubMedGoogle Scholar
  69. 69.
    Kantarcioglu B, Bekoz HS, Olgun FE, Cakal B, Arkan B, Turkoglu H, et al. Allogeneic stem cell transplantation in a blast-phase chronic myeloid leukemia patient with carbapenem-resistant Klebsiella pneumoniae tricuspid valve endocarditis: a case report. Mol Clin Oncol. 2016;5(4):347–50.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Barshay J, Nemets A, Ducach A, Lugassy G. Pseudomonas aeruginosa endocarditis in acute myeloid leukemia: a rare complication. Int J Biomed Sci. 2008;4(4):330.Google Scholar
  71. 71.
    Yong MS, Coffey S, Prendergast BD, Marasco SF, Zimmet AD, McGiffin DC, et al. Surgical management of tricuspid valve endocarditis in the current era: a review. Int J Cardiol. 2016;202:44–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Kuruvilla J, Forrest D, Lavoie J, Nantel S, Shepherd J, Song K, et al. Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;34(11):969.CrossRefPubMedGoogle Scholar
  73. 73.
    Chrissoheris MP, Libertin C, Ali RG, Ghantous A, Bekui A, Donohue T. Endocarditis complicating central venous catheter bloodstream infections: a unique form of health care associated endocarditis. Clin Cardiol. 2009;32(12):E48–54.CrossRefPubMedGoogle Scholar
  74. 74.
    Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, Martinelli G, et al. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol. 2008;81(5):354–63.PubMedGoogle Scholar
  75. 75.
    Roguin A, Reisner S. Right atrial mass related to indwelling central venous catheters in patients undergoing dialysis. Eur J Echocardiogr. 2000;1(3):222–3.CrossRefPubMedGoogle Scholar
  76. 76.
    Kale SB, Raghavan J. Tricuspid valve endocarditis following central venous cannulation: the increasing problem of catheter related infection. Indian J Anaesth. 2013;57(4):390.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Liepman MK, Jones PG, Kauffman CA. Endocarditis as a complication of indwelling right atrial catheters in leukemic patients. Cancer. 1984;54(5):804–7.CrossRefPubMedGoogle Scholar
  78. 78.
    Kravitz MS, Shoenfeld Y. Thrombocytopenic conditions—autoimmunity and hypercoagulability: commonalities and differences in ITP, TTP, HIT, and APS. Am J Hematol. 2005;80(3):232–42.CrossRefPubMedGoogle Scholar
  79. 79.
    Solomons P. Acute promyelocytic leukaemia associated with acute myocardial infarction-a case report. S Afr Med J. 1986;70(1):117–8.PubMedGoogle Scholar
  80. 80.
    Cappelli F, Porciani MC, Bergesio F, Perlini S, Attanà P, Moggi Pignone A, et al. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging. 2011;13(5):416–22.CrossRefPubMedGoogle Scholar
  81. 81.
    Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45–59.PubMedGoogle Scholar
  82. 82.
    Hassan W, Al-Sergani H, Mourad W, Tabbaa R. Amyloid heart disease: new frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J. 2005;32(2):178.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898–909.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Child JS, Levisman JA, Abbasi AS, MacAlpin RN. Echocardiographic manifestations of infiltrative cardiomyopathy: a report of seven cases due to amyloid. Chest. 1976;70(6):726–31.CrossRefPubMedGoogle Scholar
  85. 85.
    Lehtonen J, Kettunen P. Pulmonary hypertension as a dominant clinical picture in a case of amyloidosis and smoldering multiple myeloma. Int J Cardiol. 2007;115(1):E29–30.CrossRefPubMedGoogle Scholar
  86. 86.
    Bellavia D, Pellikka PA, Dispenzieri A, Scott CG, Al-Zahrani GB, Grogan M, et al. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging. 2012;13(8):680–9.CrossRefPubMedGoogle Scholar
  87. 87.
    Klein AL, Hatle LK, Burstow DJ, Taliercio CP, Seward JB, Kyle RA, et al. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990;15(1):99–108.CrossRefPubMedGoogle Scholar
  88. 88.
    Griffiths B, Hughes P, Dowdle R, Stephens M. Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax. 1982;37(9):711.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ana-Maria Vintilă
    • 1
  • Mihaela Horumbă
    • 2
  • Vlad Damian Vintilă
    • 3
  1. 1.Department of Internal MedicineColţea Clinical Hospital, “Carol Davila” University of Medicine and PharmacyBucharestRomania
  2. 2.Department of Internal MedicineColţea Clinical HospitalBucharestRomania
  3. 3.Department of CardiologyUniversity Emergency Hospital, “Carol Davila” University of Medicine and PharmacyBucharestRomania

Personalised recommendations